Biotech Values

[stockbettor]

Seems to me the more consequential trial will be the second P3 Biogen is running, which includes a Copaxone arm:

In addition to DEFINE, another Phase 3 RRMS clinical trial, CONFIRM, is currently underway. This study is evaluating BG-12 and an active reference comparator, glatiramer acetate, against placebo on clinical relapse, magnetic resonance imaging (MRI) measures of MS, progression of disability, and safety. Results from CONFIRM are expected in the second half of 2011.

http://www.biogenidec.com/PRESS_RELEASE_DETAILS.aspx?ID=5981&ReqId=1548648

http://clinicaltrials.gov/ct2/show/NCT00451451